"Nope, not at all. We are wrapping up. Dr. Arad is

"Nope, not at all. We are wrapping up. Dr. Arad is very happy to be getting this done. No one happy it’s taken this long, but other activities have not slowed down"
https://twitter.com/G_Commish/status/14988050...A&s=19

"Waiting for the ink on the agreement to release the news. I’m not saying anything else because because nothing else I say matters. Finished with tax and legal, now just waiting for entity to be formed"
https://twitter.com/G_Commish/status/14974613...g&s=19

There is no new shiny focus. It’s the natural evolution of Tollovid and part of the reason why Tollovid Daily deprioritized for time being. Many supplements have become OTC products once data is in hand. 3CL entity focus on Tollo products. Todos is testing revs+Videssa.
https://twitter.com/G_Commish/status/14990303...A&s=19

"Topic switched to Videssa! Videssa starting to get attention now that people understand Grail’s test is being used to screen for breast cancer with poor sensitivity. Videssa solves this problem. TBIA could deliver on Grail’s promise re: all cancer screen. Videssa is game-changer"

This is very clear.
Deals closing (closed) forming 3CL Sciences
3CL Sciences will handle all things Tollo worldwide
Tollovid®, (Tollovid Daily™)?, Tollovir™ and TolloTest™

Todos remains focused and is fact pushing forward Videssa now for two reasons, first "Grail’s test is being used to screen for breast cancer with poor sensitivity. Videssa solves this problem. " and second
$TOMDF Appoints Greg Meiselbach as Vice President of Government Affairs.

Many established contacts in government through his work at BIO
Ahttps://twitter.com/G_Commish/status/1501228674976485377?t=JeLrXA8MOkmgpg1o_k5Ang&s=19

He will be driving the interactions with governments, especially with his already established relationships and taking over the conversations we have ongoing with various health ministries.
https://twitter.com/G_Commish/status/15012260...A&s=19


And as for ACC, AssClownCrew, the ignorance being spewed or plain lies about what's going on, here's a good reminder of how secure this deal is.

Todos and NLC Pharma are currently operating under our active joint venture with NLC Pharma called COVID Antigen Test Killer (CATK) established in Q2/2020 where Todos has been funding the development and commercialization of 3CL protease biology-related products that include Tollovid®, Tollovid Daily™, Tollovir™ and TolloTest™. As a reminder, Dr. Dorit Arad of NLC Pharma is a pioneer in the field of 3CL protease biology whose lab was the first to purify the 3C and 3CL proteases in the early 2000s and is slated to become the Chief Scientific Officer of 3CL Sciences.
https://www.biospace.com/article/releases/tod...reholders/

News not quite forthwith, but soon.

Thoughts to chew on during these dips.